Core Points - The company announced that it raised a net amount of 1.304 billion yuan through a private placement of shares in 2016, originally intended for investment in the health industry and other projects [1] - In 2022, the company revised part of its project allocations, designating 678 million yuan for the construction of a traditional Chinese medicine production base and 328 million yuan for permanent working capital [1] - The company has previously utilized idle raised funds to purchase financial products or structured deposits, totaling 575 million yuan as of September 30, 2025 [1] - The company plans to continue using no more than 850 million yuan of idle raised funds to purchase related products, with the funds being allowed for rolling use and the authorization valid for one year [1]

Core Viewpoint - The company has announced the use of part of its idle raised funds to temporarily supplement working capital and for cash management, ensuring compliance with relevant regulations and maintaining the integrity of its fundraising purposes [13][25]. Financial Data - The company reported a net profit of 58.7371 million yuan after excluding share-based payment expenses for the first three quarters of 2025 [4]. - As of September 30, 2025, the company had repurchased a total of 1,413,421 shares, accounting for 0.8377% of the total share capital, with a total expenditure of approximately 38.59 million yuan [10]. Shareholder Information - The company has implemented an employee stock ownership plan to enhance employee motivation and company competitiveness, with a lock-up period of 12 months for the purchased shares [8]. Use of Idle Funds - The company plans to use up to 35 million yuan of idle raised funds to temporarily supplement working capital for daily operations related to its main business, with a usage period not exceeding 12 months [13][20]. - The company has previously returned 45 million yuan of temporarily used funds within the stipulated timeframe, ensuring no impact on the normal execution of fundraising investment plans [18]. Cash Management - The company intends to use up to 15 million yuan of temporarily idle raised funds for cash management, focusing on low-risk financial products to enhance cash asset returns while ensuring the safety of the funds [25][29]. - The cash management will be conducted under strict compliance with relevant regulations, and the company will monitor the investment products closely to mitigate risks [39].

Core Viewpoint - Jiacheng International (603535) has seen a stock price increase of 9.04% this week, closing at 12.42 yuan, with a total market capitalization of 6.295 billion yuan as of September 12, 2025 [1] Company Announcements - The fifth board of directors held its 23rd meeting on September 9, 2025, where it approved the use of up to 250 million yuan of temporarily idle raised funds to supplement working capital and the use of up to 28 million yuan for cash management, with unanimous approval from all present [1][2] - The company has completed the original fundraising project "Cross-border E-commerce Smart Logistics Center," with remaining funds of 239.8882 million yuan being redirected to the "Free Trade Port Cloud Intelligence International Distribution Center" project [2][4] - The previous use of idle raised funds for working capital has been fully repaid [4] Financial Management - The board has authorized management to make investment decisions within the approved limits for cash management, focusing on low-risk, capital-preserving financial products issued by banks or other financial institutions [2][3] - As of June 30, 2025, a total of 512.6717 million yuan of raised funds has been invested, with ongoing construction for the "Free Trade Port Cloud Intelligence International Distribution Center" project [3]

Core Viewpoint - The company, Shaanxi Meibang Pharmaceutical Group Co., Ltd., has announced the use of temporarily idle raised funds for cash management, specifically through a financial product with a total investment of 15 million yuan [1][4]. Group 1: Financial Management - The entrusted financial management is conducted by CITIC Bank, with a total amount of 15 million yuan allocated to the "Anying Xiang Fixed Income Stable Profit One Month Holding Period 32 C" product [1][7]. - The company aims to enhance the efficiency of fund utilization while ensuring that the investment projects funded by the raised capital are not affected [4][11]. - The maximum amount approved for cash management is 20 million yuan from idle raised funds and 60 million yuan from idle self-owned funds, with the ability to roll over the amount within the validity period of the resolution [1][8]. Group 2: Previous Financial Management - The previous financial management involved the redemption of funds from a product named "Tongying Xiang Fixed Income Stable Seven-Day Holding Product 1," with actual returns aligning with expectations [2][3]. - The company has utilized a total of 9 million yuan in financial products over the last twelve months, with a maximum single-day investment of 3 million yuan, representing 2.67% of the net assets for the past year [13]. Group 3: Investment Product Details - The current financial product has a duration of 30 days, with an expected annualized return rate of 3.86% [7]. - The company ensures that the investment products are of high safety and liquidity, complying with the requirements for cash management without altering the intended use of raised funds [6][11]. Group 4: Approval Process - The decision to use idle funds for cash management was approved during the third board meeting and the fifth supervisory board meeting held on April 24, 2025, and subsequently ratified at the annual shareholders' meeting on May 16, 2025 [1][8]. - The supervisory board and the sponsor institution have both expressed agreement with the company's cash management strategy, confirming compliance with relevant regulations [11].